First-of-its-kind facility for Merck in China to meet local demand

22-Sep-2022

Merck opened a viral clearance (VC) laboratory as part of the first building phase of its new €29million China Biologics Testing Center. The 5,000 square meter center is the first of its kind for Merck in China. The VC laboratory allows customers to locally conduct viral clearance studies from ...

more

Creates more than 800 jobs by the end of 2028

12-Sep-2022

Merck strengthens its manufacturing capabilities for single-use assemblies, a key technology for the production of Covid-19 vaccines and other lifesaving therapies, by investing more than €130million in Molsheim, France. The investment is the largest ever in the 50-year history of the site and ...

more

29-Aug-2022

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. entered into a global licensing agreement with Merck for the use of Biocytogen’s RenMiceTM platform. Under the terms of the agreement, Merck will have full access to Biocytogen’s RenMiceTM platform to discover and develop fully human antibody ...

more

Supports strategy to add physical capacity and expand regional network in the United States

22-Jul-2022

The Life Science business of Merck broke ground at its Sheboygan, Wisconsin site, for the company’s first lateral flow membrane production facility in the United States. Lateral flow membranes are a key component in rapid diagnostic test kits for a variety of applications, including Covid-19 ...

more

Prizewinner from the Max Planck Institute in Marburg, Germany is working on capturing carbon dioxide and converting it into new chemical building blocks using biocatalysts

15-Jul-2022

Merck announced the winner of the 2022 Future Insight Prize in the category of “Energy”. The €1million prize was awarded at the “Curious2022 – Future Insight” scientific conference in Darmstadt, Germany, to Professor Tobias Erb (43), Director at the Max Planck Institute for Terrestrial ...

more

Expansion doubles production of the most highly potent active pharmaceutical ingredients (HPAPIs)

27-Jun-2022

Merck announced that its Life Science business sector has doubled its high-potent active pharmaceutical ingredients (HPAPI) production capacity with the expansion of its facility in Verona, near Madison, Wisconsin, USA. This new €59 million, 70,000 square foot facility, officially opened, brings ...

more

Collaboration will help enable real-time release and Bioprocessing 4.0

15-Jun-2022

Merck announced that it has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0. “The biopharmaceutical industry is on a ...

more

09-Jun-2022

Proxygen announced that the company has entered into a strategic multi-year research collaboration and license agreement with Merck. Proxygen is eligible to receive up to€495 million ($554 million at the average USD/EUR FX rate of Q1 2022)in continuous R&D funding, upfront and success-based ...

more

“The investment in Cork is the biggest site investment in the history of our Life Science business”

24-May-2022

Merck is expanding its membrane and filtration manufacturing capabilities in Ireland. The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland. The ...

more

High margins in all three businesses despite challenging economic headwinds and increasing global uncertainty

12-May-2022

Merck achieved strong results in the first quarter of 2022. Net sales increased by 12.2% to € 5,198 million compared with the year-earlier quarter. All three business sectors contributed to this growth. The key drivers were the company’s Big3 businesses – the Process Solutions business of Life ...

more